Therapeutic Response

TP53 deletion status confers therapeutic sensitivity to Zanubrutinib in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Zanubrutinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.